Free shipping on all orders over $ 500

Moxifloxacin

Cat. No. M3720
Moxifloxacin Structure
Size Price Availability Quantity
100mg USD 50  USD50 In stock
500mg USD 110  USD110 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Moxifloxacin possibly stimulates lipid peroxidation and enhances phagocytosis, as depicted by MDA production and survival prolongation, without being toxic as depicted by white blood cell count. Moxifloxacin-containing triple therapy, a recommended second-line treatment for initial concomitant or sequential therapy failure, had insufficient efficacy. Moxifloxacin reportedly exhibits immunomodulatory properties, but experimental evidence in pneumonia is lacking. Moxifloxacin has limited phototoxic potential. In clinical trials, moxifloxacin had clinical success rates of 88-97% and bacteriologic eradication rates of 90-97%. Moxifloxacin is a safe and effective antimicrobial that will be useful for treating acute sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.

Chemical Information
Molecular Weight 401.43
Formula C21H24FN3O4
CAS Number 151096-09-2
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Müller-Redetzky HC, et al. J Antimicrob Chemother. Moxifloxacin is not anti-inflammatory in experimental pneumococcal pneumonia.

[2] Chung KH, et al. Gut Liver. The Efficacy of Moxifloxacin-Containing Triple Therapy after Standard Triple, Sequential, or Concomitant Therapy Failure for Helicobacter pylori Eradication in Korea.

[3] Balfour JA, et al. Drugs. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.

Related Topoisomerase Products
ICRF-193

ICRF-193 is an TopoII inhibitor.

Topoisomerase II inhibitor 15

Topoisomerase II inhibitor 15 is a Topoisomerase II inhibitor.

Topoisomerase II inhibitor 13

Topoisomerase II inhibitor 13 is a topoisomerase II (Topo II) inhibitor.

ICRF-196

ICRF-196 is an racemic mixture of the (S,S)- and (R,R)-isomers of ICRF-193.

Cholesteryl hemisuccinate

Cholesteryl hemisuccinate is a with hepatoprotective an anticancer activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: Moxifloxacin supplier, Topoisomerase, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.